Allogene Therapeutics reported a narrower-than-expected loss for Q4 2024, with an EPS of -$0.28, surpassing the forecast of -$0.32. The company’s stock responded positively, rising 3.66% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback